Claudine Bruck - Annovis Bio Independent Director

Annovis Bio Management Efficiency

The company has return on total asset (ROA) of (1.5458) % which means that it has lost $1.5458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.967) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio's management efficiency ratios could be used to measure how well Annovis Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 7.61 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23). At this time, Annovis Bio's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 53.7 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23).

Similar Executives

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people. Annovis Bio (ANVS) is traded on New York Stock Exchange in USA. It is located in 101 Lindenwood Drive, Malvern, PA, United States, 19355 and employs 6 people. Annovis Bio is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Annovis Bio Leadership Team

Annovis Stock Performance Indicators

Additional Tools for Annovis Stock Analysis